PMID- 22998639
OWN - NLM
STAT- MEDLINE
DCOM- 20130304
LR  - 20181202
IS  - 1528-1167 (Electronic)
IS  - 0013-9580 (Linking)
VI  - 54
IP  - 1
DP  - 2013 Jan
TI  - Rapid loading of intravenous lacosamide: efficacy and practicability during 
      presurgical video-EEG monitoring.
PG  - 75-80
LID - 10.1111/j.1528-1167.2012.03651.x [doi]
AB  - PURPOSE: This study investigates immediate efficacy and safety of intravenous 
      application of de novo lacosamide (LCM) as add-on therapy in patients with 
      pharmacoresistant focal epilepsy. METHODS: During presurgical 
      video-electroencephalography (EEG) monitoring, 17 adult inpatients received LCM 
      infusion (200 mg every 12 h for 2-3 days) followed by oral formulation with the 
      same regimen. Before and after intravenous application of LCM, seizures and 
      interictal epileptiform discharges (IEDs) recorded with continuous video-EEG 
      monitoring were analyzed, and an assessment of adverse events (AEs) was performed 
      daily. To evaluate the midterm tolerability and efficacy, follow-up visits were 
      conducted 1 and 3 months after discharge from hospital. KEY FINDINGS: In the 
      acute phase, intravenous initiation of LCM was well tolerated with few mild or 
      moderate AEs (3 of 17, 17.6%). A significant reduction of seizure frequency in 
      the treatment phase as compared to mean seizure frequency in the 2-day baseline 
      phase was achieved (p < 0.05 for the first treatment day, and p < 0.005 for the 
      second treatment day). On the first treatment day, 61.5% of the patients were 
      seizure free, and 84.6% on the second treatment day. IED reduction after 
      intravenous application of LCM was not significant. After 1 month, the 50% 
      responder rate was 46.6% and after the 3-month period, 42.8%. SIGNIFICANCE: Our 
      data suggest that rapid intravenous initiation of de novo LCM is safe and may 
      protect against seizures in a rapid and midterm time window.
CI  - Wiley Periodicals, Inc. (c) 2012 International League Against Epilepsy.
FAU - Li, Wenjie
AU  - Li W
AD  - Department of Neurology, University of Magdeburg, Magdeburg, Germany Neurological 
      Clinic, University Hospital Erlangen, Erlangen, Germany.
FAU - Stefan, Hermann
AU  - Stefan H
FAU - Matzen, Julia
AU  - Matzen J
FAU - Rampp, Stefan
AU  - Rampp S
FAU - Heinze, Hans-Joachim
AU  - Heinze HJ
FAU - Schmitt, Friedhelm C
AU  - Schmitt FC
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20120921
PL  - United States
TA  - Epilepsia
JT  - Epilepsia
JID - 2983306R
RN  - 0 (Acetamides)
RN  - 0 (Anticonvulsants)
RN  - 563KS2PQY5 (Lacosamide)
SB  - IM
MH  - Acetamides/administration & dosage/adverse effects/*therapeutic use
MH  - Administration, Oral
MH  - Adult
MH  - Anticonvulsants/administration & dosage/adverse effects/*therapeutic use
MH  - Drug Administration Schedule
MH  - Electroencephalography
MH  - Epilepsies, Partial/*drug therapy/physiopathology
MH  - Female
MH  - Humans
MH  - Infusions, Intravenous
MH  - Lacosamide
MH  - Male
MH  - Treatment Outcome
EDAT- 2012/09/25 06:00
MHDA- 2013/03/05 06:00
CRDT- 2012/09/25 06:00
PHST- 2012/09/25 06:00 [entrez]
PHST- 2012/09/25 06:00 [pubmed]
PHST- 2013/03/05 06:00 [medline]
AID - 10.1111/j.1528-1167.2012.03651.x [doi]
PST - ppublish
SO  - Epilepsia. 2013 Jan;54(1):75-80. doi: 10.1111/j.1528-1167.2012.03651.x. Epub 2012 
      Sep 21.